Study shows use of EpiSwitch blood test can aid in treatment decision for rheumatoid arthritis

A study using Oxford BioDynamics’ EpiSwitch showed the blood test that looks for epigenetic biomarkers can help identify an inadequate response to using methotrexate (MTX) in treating early rheumatoid arthritis.

The study, which was recently published in the Journal of Translational Medicine, looked into whether the differences in genomic architecture represented by a chromosome conformation signature (CCS) in blood taken from people with early rheumatoid arthritis before they were administered methotrexate to see what the likelihood was that they would respond to such first-line disease-modifying antirheumatic drugs (DMARDs).

MTX is a primary treatment for new-onset rheumatoid arthritis; however, many patients do not respond to the therapy that can take at least six months for an indication of its effectiveness. In the meantime, substantial damage due to inflammation can occur during that timeframe, resulting in future disability and loss of function.

Results of the study “successfully showed that a CCS found in the blood samples” using the EpiSwitch was able to identify “with a high degree of accuracy” patients who wouldn’t respond well to MTX.

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Share on facebook
    Share on twitter
    Share on linkedin
    Oxford BioDynamics

    More articles like this

    Oxford BioDynamics

    How are EpiSwitch markers detected?

    Introduction: Getting the basics right Oxford BioDynamics’ (OBD) EpiSwitch™ biomarker discovery platform combined with their newly enhanced detection technology gives the company valuable quantitative insights into chromosome conformations (DNA protein complexes) that regulate normal and disease biology in

    Oxford BioDynamics

    What is EpiSwitchTM and how is it used?

    Oxford BioDynamics’ EpiSwitch™ technology is based on epigenetics, mechanisms that alter gene expression without altering the underlying DNA sequence and whose deregulation plays a role in the development of cancer, autoimmune, and neurologic diseases. Although DNA is often

    Oxford BioDynamics

    Sanders-Brown research highlights form of severe dementia

    The long-running study on aging and brain health at the University of Kentucky’s Sanders-Brown Center on Aging (SBCoA) Alzheimer’s Disease Center has once again resulted in important new findings – highlighting a complex and under-recognized form of dementia.

    Oxford BioDynamics

    Researchers identify new genetic defect linked to ALS

    Mutations in the UBQLN2 gene, known to cause amyotrophic lateral sclerosis (ALS), promote the buildup of toxic waste in brain cells by preventing the normal function of two cellular degradation mechanisms, a study has found. In addition to its known role in the proteasome,